Article · 28 Feb 2025
Conference abstractPublished 16 Oct 2017
The development of liver toxicity knowledge base to support the assessment of drug-induced liver injury risk in humans
US Food and Drug Administration, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Drug-Induced Liver Injury (DILI) is a frequent cause of Adverse Drug Reaction (ADR) resulting in clinical trial failure, warnings and withdrawals of numerous medications. Despite the research community’s best efforts, current testing strategies aimed at identifying hepatotoxic drugs prior to human trials are not sufficiently powered to predict the complex mechanisms leading to DILI. Tremendous efforts were conducted to fulfill this knowledge gap. In the FDA’s National Center for Toxicological Research, we developed the Liver Toxicity Knowledge Base (LTKB), aiming to improve our understanding and the prediction of DILI risk in humans via integrative analysis of diverse drug-elicited data. In this practice, we discovered that several drug properties and toxicological properties, such as daily dose, lipophilicity and the capability to form Reactive Metabolites (RM), are strongly associated with serious DILI potential in humans. Here, we will introduce the rule-of-two model (i.e. daily dose≥100 mg/day and logP≥3) and DILI score model (i.e. a scoring model derived from daily dose, logP and formation of RM) developed by the NCTR research team. We will discuss the applications of these models in the context of regulatory processes with the discussion of independent validations reported in literature. Our studies suggest that these predictive models (e.g. RO2, DILI score) could help better assess the human DILI risk in drug development process.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 24 Jul 2017
CYP2E1 polymorphism, acetylator profiles and drug-induced liver injury incidence of Indonesian tuberculosis patients
Opinion · 25 Sep 2024
Drug-Induced Liver Injury (DILI): Mechanisms, Risk Factors and Emerging Protective Therapies
Short communication · 29 Nov 2025
Understanding Drug-Induced Liver and Pancreatic Toxicity
Article · 22 Dec 2023
Analysis of Clinical Features and Imaging Manifestations of Drug-Induced Liver Injury after Treatment of Colorectal Cancer
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectGastroenterology & Hepatology
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Minjun Chen”
